Prostate cancer stands as the most frequently detected malignant condition among men, ranking as the second primary contributor to cancer-linked fatalities in Western society. While localized prostate cancer can be addressed through various efficient treatments, nearly all patients eventually advance to the state of incurable metastatic castration-resistant prostate cancer. Given the substantial toll on both mortality and quality of life due to the disease’s progression, there exists a pressing demand for novel, precisely targeted therapeutic interventions.

Targeted radionuclide therapy is an increasingly favored treatment option for prostate cancer, attributed to its ability to administer a greatly concentrated absorbed dose precisely to the intended tumor site, all the while safeguarding the neighboring healthy tissues. 

In this podcast, we hear from Jeremie Calais, MD, MSc, University of California, Los Angeles, CA, Scott Tagawa, MD, MS, FACP, Weill Cornell Medical Center, New York, NY, and Shahneen Sandhu, MBBS, FRACP, Peter MacCallum Cancer Centre, Melbourne, Australia, on some of the latest updates in targeted radionuclide therapy for prostate cancer.